CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

The time point for Hansa Medical’s Third Quarter 2017 Business Update Conference Call has been changed

9 Nov 2017, 14:00
As previously announced on 7 November 2017, Hansa Medical will publish its report for the third quarter of 2017 at 08:00AM CET on Tuesday, 14 November 2017. The time for the conference call has been changed from 2:00PM CET to 11:00AM CET on the same day.

The presentation will be held in English and will be hosted by Hansa Medical’s Acting CEO Ulf Wiinberg. Slides used in the presentation will be live on the company’s website during the call under Events & Webcast and will also be made available after the call. To participate in the telephone conference, please call:

SE: +46 (0) 856 642 691
UK: +44 (0) 2030 089 803
US: +1 855 831 5945

A link to audio cast can be found on the Hansa Medical website under Events & Webcasts or here: https://tv.streamfabriken.com/hansa-medical-q3-2017

Files

For further information, please contact:
Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46707175477
E-mail: emanuel.bjorne@hansamedical.com

Cord Communications, Stockholm
Mikael Widell
Mobile: +46 70 311 9960

Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.